Loading...
Market
What will be the FDA approval status of a drug discovered with Triomics' AI platform by the end of 2025?
5
Resolution / Starting Odds
Approved • 33%
Rejected • 33%
Pending • 34%
FDA announcement and healthcare regulatory news
Story
Triomics Raises $15M Series A, Led by k__sarim and hrituraj1997, for AI Cancer Care
May 9, 2024, 05:06 PM
Triomics, a US-based startup, has successfully raised $15 million in a Series A funding round to enhance oncology workflows through the automation of cancer clinical trials matching using Generative AI. The funding round saw participation from prominent investors including Y Combinator, Lightspeed Venture Partners, General Catalyst, and Nexus Venture Partners. This AI-driven platform is set to revolutionize healthcare by improving the analysis of medical data, aiding drug discovery, clinical trials, and care delivery, ultimately benefiting doctors and patients alike. The team, led by k__sarim and hrituraj1997, is at the forefront of this transformative technology.
View original story
Similar markets
Antibiotic A • 33%
Antibiotic B • 33%
Antibiotic C • 33%
Oncology • 25%
Cardiovascular • 25%
Neurology • 25%
Immunology • 25%
80-90% success • 50%
Below 80% success • 50%
